Pulmocide
Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.
3
Funding Rounds
$152.8m
Money raised
Overview
Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.
- Website:
- Headquarters: London
- Social accounts: linkedin
Funding
Funding series
Funding Series Analysis
The company Pulmocide has raised a total of $122.4m in funding over 3 rounds.
Key Insights:
- Pulmocide Series C round, May 2021: $92m
- Pulmocide Series B round, March 2017: $30.4m
- Pulmocide funding round, March 2017: $30.4m
Pulmocide Series C round, May 2021
$92m
Pulmocide Series B round, March 2017
$30.4m
Pulmocide funding round, March 2017
$30.4m
Industries
Pulmocide is active in the following industries: